November 12, 2009 The combined-modality care of the patient with colon or rectal cancer metastatic to the liver demands a team approach. It is little wonder that there is much confusion about this topic, given the number of unique treatment options that are delivered in a sequential and reiterative process. The concept of multidisciplinary approaches to complex cancer challenges has been adopted for a variety of tumor types and situations. More »April 27, 2009 Since the early 1990s, postoperative adjuvant chemoradiotherapy was widely viewed as the main approach to treat patients with stage II and III rectal cancer. Over the past few years, significant efforts have shifted towards developing neoadjuvant approaches, which combine chemotherapy with radiotherapy prior to surgical resection. More »March 19, 2009 SAN FRANCISCO—Routine KRAS testing in colon cancer patients received a major boost in January when ASCO issued a provisional clinical statement in favor of pretreatment genetic screening in metastatic disease. But KRAS is only the first step toward personalized medicine in colorectal cancer, according to reports presented at the 2009 Gastrointestinal Cancers Symposium. In fact, colon cancer treatment is headed in the same direction as breast cancer, with other genetic polymorphisms emerging as... More »February 25, 2009 STOCKHOLM—For rectal cancer patients, a multidisciplinary team is critical to success because it increases the possibility of a curative resection, Andres Cervantes, MD, associate professor of medicine at University Hospital, Valencia, Spain, said at ESMO 2008. “Every patient should be treated within an expert multidisciplinary team,” he emphasized. More »November 1, 2008 Minsky and Guillem should be commended for this excellent review and for addressing major areas of controversy in the management of rectal cancer. More »June 1, 2008 Neoadjuvant chemoradiation has become the favored adjuvant treatment for stages II and III rectal cancer. Compared to postoperative chemoradiation, this modality of treatment has been shown to be superior in terms of toxicity, local relapse, and sphincter-saving.[1] This article will focus on the evolution of neoadjuvant chemotherapy over the past 2 decades, current acceptable neoadjuvant standards, and current investigational regimens. More »August 1, 2007 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are often overexpressed in colorectal cancer and are associated with inferior outcomes. Based on successful randomized phase III trials, anti-EGFR and anti-VEGF therapeutics have entered clinical practice. Cetuximab (Erbitux), an EGFR-specific antibody, is currently approved in the United States in combination with irinotecan (Camptosar) for patients with metastatic colorectal cancer refractory to irinotecan or... More »August 1, 2007 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are often overexpressed in colorectal cancer and are associated with inferior outcomes. Based on successful randomized phase III trials, anti-EGFR and anti-VEGF therapeutics have entered clinical practice. Cetuximab (Erbitux), an EGFR-specific antibody, is currently approved in the United States in combination with irinotecan (Camptosar) for patients with metastatic colorectal cancer refractory to irinotecan or... More »August 1, 2007 Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are often overexpressed in colorectal cancer and are associated with inferior outcomes. Based on successful randomized phase III trials, anti-EGFR and anti-VEGF therapeutics have entered clinical practice. Cetuximab (Erbitux), an EGFR-specific antibody, is currently approved in the United States in combination with irinotecan (Camptosar) for patients with metastatic colorectal cancer refractory to irinotecan or... More »March 8, 2007 ROCKVILLE, Md. -- Although aspirin and NSAIDs such as ibuprofen can reduce the occurrence rate of colon cancer, they're not worth the increased risk of gastrointestinal side effects, said the U.S. Preventive Services Task Force. More »September 1, 2006 The liver is a frequent site of metastatic colorectal disease. Over the past 20 years, improvements in systemic chemotherapy and surgical techniques have improved the survival of patients with hepatic metastases. For 4 decades, fluorouracil and leucovorin were the only drugs available to treat metastatic colorectal cancer, but several new drugs and a variety of novel regimens are now available. Further improvements in results have been seen with the delivery of chemotherapy via the hepatic... More »September 1, 2006 The liver is a frequent site of metastatic colorectal disease. Over the past 20 years, improvements in systemic chemotherapy and surgical techniques have improved the survival of patients with hepatic metastases. For 4 decades, fluorouracil and leucovorin were the only drugs available to treat metastatic colorectal cancer, but several new drugs and a variety of novel regimens are now available. Further improvements in results have been seen with the delivery of chemotherapy via the hepatic... More »May 1, 2004 Adjuvant therapy with chemotherapy and/or radiation therapy in
addition to surgery improves outcome for patients with high-risk carcinomas
of the colon or rectum. For colon cancer, fluorouracil (5-FU)
combined with leucovorin is a current standard of care that improves
long-term survival. A recent European trial (MOSAIC) has documented
significant improvement in 3-year disease-free survival when oxaliplatin
(Eloxatin) was added to infusional 5-FU and leucovorin in the FOLFOX
regimen. Two US... More »May 2, 2002 The US National Cancer Institute Gastrointestinal Intergroup has contributed to the development of chemotherapy and radiation regimens for the treatment of stage II and III rectal cancer. The first Intergroup trial demonstrated improvement in relapse-free and overall survival for patients who received protracted venous infusion fluorouracil (5-FU) with radiation compared to those treated with bolus 5-FU. More »
|
Risk Assessment in Stage II Colon Cancer In this January 2010 supplement to Oncology, guest editor Axel Grothey from the Mayo Clinic, explores adjuvant therapy considerations in stage II colon cancer. This supplement and associated publication costs were funded by Genomic Health.
SearchMedica Search Result
Find peer-reviewed literature and websites for practicing medical professionals
|
